Source:http://linkedlifedata.com/resource/pubmed/id/20361743
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2010-5-6
|
pubmed:abstractText |
Oligodeoxynucleotides containing unmethylated CpG motifs act as ligands of Toll-like receptor 9 (TLR9). We previously reported a novel class of TLR9 agonists, referred to as immune-modulatory oligonucleotides (IMOs), in which two 11-mers of the same sequence are attached via their 3'-ends through a 1,2,3-propanetriol linker and contain a synthetic immune-stimulatory motif, Cp7-deaza-dG. In the present study, we have examined the impact of length, nature, and stereochemistry of the linker incorporated in agonists for TLR9 activation. The new linkers studied include (S)-(-)-1,2,4-butanetriol, 1,3,5-pentanetriol, cis,cis-1,3,5-cyclohexanetriol, cis,trans-1,3,5-cyclohexanetriol, 1,3,5-tris(2-hydroxyethyl)isocyanurate, tetraethyleneglycol, and hexaethyleneglycol in place of 1,2,3-propanetriol linker. Agonists with various linkers are studied for TLR9-mediated immune responses in HEK293 cells, human cell-based assays, and in vivo in mice. Results of these studies suggest that C3-C5 linkers, 1,2,3-propanetriol, (S)-(-)-1,2,4-butanetriol, or 1,3,5-pentanetriol, are optimal for stimulation of TLR9-mediated immune responses. Rigid C3 linkers with different stereochemistry have little effect on immune stimulation, while linkers longer than C5 reduced TLR9-mediated immune stimulation.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cross-Linking Reagents,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxyguanine Nucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Oligodeoxyribonucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 9
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1520-4804
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
13
|
pubmed:volume |
53
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3730-8
|
pubmed:meshHeading |
pubmed-meshheading:20361743-Animals,
pubmed-meshheading:20361743-Base Sequence,
pubmed-meshheading:20361743-Cell Line,
pubmed-meshheading:20361743-CpG Islands,
pubmed-meshheading:20361743-Cross-Linking Reagents,
pubmed-meshheading:20361743-Deoxyguanine Nucleotides,
pubmed-meshheading:20361743-Glycols,
pubmed-meshheading:20361743-Humans,
pubmed-meshheading:20361743-Immunologic Factors,
pubmed-meshheading:20361743-Mice,
pubmed-meshheading:20361743-Oligodeoxyribonucleotides,
pubmed-meshheading:20361743-Toll-Like Receptor 9
|
pubmed:year |
2010
|
pubmed:articleTitle |
Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.
|
pubmed:affiliation |
Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, Massachusetts 02139, USA.
|
pubmed:publicationType |
Journal Article
|